2018-2023 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Report

August 2018 | 136 pages | ID: 2F66047D8B7EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Benign Prostatic Hyperplasia (BPH) Drugs market for 2018-2023.
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.

Over the next five years, LPI(LP Information) projects that Benign Prostatic Hyperplasia (BPH) Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Alpha-Blocker
• Phosphodiesterase Type-5 Inhibitors
• 5-Alpha-Reductase Inhibitors

Segmentation by application:

• Men
• Women

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi
• ADC Therapeutics
• Bayer HealthCare
• Bristol-Myers Squibb
• Valeant Pharmaceuticals
• Endo Pharmaceuticals
• Foresee Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

RESEARCH OBJECTIVES

• To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments.
• Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Benign Prostatic Hyperplasia (BPH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

2018-2023 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS CONSUMPTION MARKET REPORT

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2023
  2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
  2.2.1 Alpha-Blocker
  2.2.2 Phosphodiesterase Type-5 Inhibitors
  2.2.3 5-Alpha-Reductase Inhibitors
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
  2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
  2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2013-2018)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
  2.4.1 Men
  2.4.2 Women
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
  2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
  2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value and Market Share by Application (2013-2018)
  2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2013-2018)

3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY PLAYERS

3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players
  3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2016-2018)
  3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players (2016-2018)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players
  3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Players (2016-2018)
  3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players (2016-2018)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY REGIONS

4.1 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
  4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions
  4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions
4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth

5 AMERICAS

5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
  5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
  5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
  6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
  6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
  7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
  7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
  8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer

11 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET FORECAST

11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2018-2023)
11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
  11.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions (2018-2023)
  11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type
11.8 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Astellas Pharma
  12.1.1 Company Details
  12.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Astellas Pharma News
12.2 Eli Lilly
  12.2.1 Company Details
  12.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Eli Lilly News
12.3 GlaxoSmithKline
  12.3.1 Company Details
  12.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 GlaxoSmithKline News
12.4 Sanofi
  12.4.1 Company Details
  12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 Sanofi News
12.5 ADC Therapeutics
  12.5.1 Company Details
  12.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 ADC Therapeutics News
12.6 Bayer HealthCare
  12.6.1 Company Details
  12.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 Bayer HealthCare News
12.7 Bristol-Myers Squibb
  12.7.1 Company Details
  12.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 Bristol-Myers Squibb News
12.8 Valeant Pharmaceuticals
  12.8.1 Company Details
  12.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 Valeant Pharmaceuticals News
12.9 Endo Pharmaceuticals
  12.9.1 Company Details
  12.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Endo Pharmaceuticals News
12.10 Foresee Pharmaceuticals
  12.10.1 Company Details
  12.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
  12.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.10.4 Main Business Overview
  12.10.5 Foresee Pharmaceuticals News

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Table Product Specifications of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure Market Research Methodology
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth Rate 2013-2023 (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Growth Rate 2013-2023 ($ Millions)
Table Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region 2013-2023 ($ Millions)
Figure Product Picture of Alpha-Blocker
Table Major Players of Alpha-Blocker
Figure Product Picture of Phosphodiesterase Type-5 Inhibitors
Table Major Players of Phosphodiesterase Type-5 Inhibitors
Figure Product Picture of 5-Alpha-Reductase Inhibitors
Table Major Players of 5-Alpha-Reductase Inhibitors
Table Global Consumption Sales by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018) ($ million)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Type (2013-2018) ($ Millions)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Type (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2013-2018)
Figure Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Men
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Men (2013-2018) (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Men (2013-2018) ($ Millions)
Figure Global Men YoY Growth ($ Millions)
Figure Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Women
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Women (2013-2018) (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Women (2013-2018) ($ Millions)
Figure Global Women YoY Growth ($ Millions)
Table Global Consumption Sales by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Application (2013-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2013-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2016-2018) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players (2016-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Players (2016-2018) ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players (2016-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players in 2016
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players (2016-2018)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players in 2017
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area by Players
Table Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
Table Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions 2013-2018 (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Regions 2013-2018
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Regions 2013-2018
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions 2013-2018 ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions 2013-2018
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions 2013-2018
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 ($ Millions)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 ($ Millions)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 ($ Millions)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 ($ Millions)
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) ($ Millions)
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)
Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) ($ Millions)
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) ($ Millions)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) ($ Millions)
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)
Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 ($ Millions)
Table Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table Benign Prostatic Hyperplasia (BPH) Drugs Customer List
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth Rate Forecast (2018-2023) (K MT)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Growth Rate Forecast (2018-2023) ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Countries (2018-2023) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Forecast by Regions
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Countries (2018-2023) ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Regions
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Type (2018-2023) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Type (2018-2023) ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Type (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Application (2018-2023) (K MT)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share Forecast by Application (2018-2023)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Application (2018-2023) ($ Millions)
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Application (2018-2023)
Table Astellas Pharma Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Eli Lilly Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table GlaxoSmithKline Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Sanofi Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table ADC Therapeutics Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Bayer HealthCare Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Valeant Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Endo Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)
Table Foresee Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
Figure Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)